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Abstract:  
An association between blood markers of thrombosis and haemostasis and cognitive decline 
has been described.  These results may be confounded by lifestyle and environmental 
factors.  We used a Mendelian Randomisation approach to describe association between 
thrombosis/haemostasis genotypes and cognition. 
We studied genetic variants (single nucleotide polymorphisms) of circulating markers of 
thrombosis and haemostasis.  Our chosen blood factors and associated polymorphisms 
were: D-dimer [rs12029080], fibrinogen [rs1800789], plasminogen activator inhibitor 
[rs2227631], von Willebrand factor [rs1063857]).  We described association with multi-
domain cognitive test scores using data from the Scottish Family Health Study.  Cognitive 
data were analysed for individual tests and combined to give a general cognitive factor. 
In 20,288 subjects we found no evidence of association between cognitive function 
(individual tests and combined scores) and any of the above-mentioned single nucleotide 
polymorphisms.  Lower scores on cognitive measures were associated with:increasing age, 
socioeconomic deprivation, blood pressure, waist-hip ratio, smoking, and vascular 
comorbidity (all p<0.001).  In a post-hoc sensitivity analysis restricted to those aged over 50 
years there was still no signal of association.  
Our data add to our understanding of determinants of cognition but are not definitive, the 
variation in blood levels explained by SNPs was modest and our sample size may have 
been insufficient to detect a modest association.   
 
Keywords: cognition disorders; dementia; hemostasis; genomics; Mendelian randomization 
analysis;  
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Introduction 
Cognitive decline and dementia are a substantial and growing public health concern. To 
date, our understanding of pathogenesis and risk factors is limited and this has impacted on 
development of effective therapies.(Ritchie et al 2015)  
Various cohort and case-control based studies have described an apparent association 
between higher levels of blood markers of thrombosis and haemostasis and incident 
dementia or cognitive decline.(Bots et al 1998, Gallacher et al 2010, Stott et al 2010))  
Recent systematic review and meta-analysis has confirmed this link with blood markers, 
observed associations were strongest for “vascular” dementia but also apparent for “all 
cause” (undifferentiated) dementias.(Quinn et al 2011)  The summary data on strength of 
associations were modest with wide confidence intervals but were consistent across the 
available data.  A particular association between dementia and markers of thrombin 
generation (D-dimer and prothrombin fragment 1+2) and endothelial dysfunction (von 
Willebrand factor [vWF] and plasminogen activator inhibitor 1 [PAI1]) was apparent. 
There are many typical biases that will affect the validity of these epidemiological studies.  
Association may be a result of disease rather than causal or may reflect confounding by 
other factors.  For example, thrombosis/haemostasis factors may be associated with 
vascular disease that causes cognitive decline, thus representing an indirect association.  
Even in robust studies, statistical adjustment for confounding is often incomplete as only 
certain known factors will be measured.(Fewell et al 2007)  Of particular importance in this 
context, haemostatic and thrombotic blood markers of interest are influenced by several 
demographic, clinical and lifestyle factors that may also impact on cognition and so may 
confound any apparent association.(Bath et al 2010)   
A potential approach to establish causation is to describe the association of an outcome of 
interest (in this case, cognition) with genetic markers that relate to the postulated causative 
factor (in this case, genetic variants that determine thrombosis and haemostasis).  This 
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“Mendelian randomisation” strategy can provide important suggestive evidence about 
causality by incorporating fixed genetic information into the traditional epidemiological study 
design.(Davey Smith et al 2014) 
We performed Mendelian randomisation analyses of the genetic determinants of 
thrombosis/haemostasis and compared with population cognitive test scores in a large, 
community dwelling adult population. Our aim was to describe the role of 
thrombosis/haemostasis in cognitive capability, free from the usual lifestyle and 
environmental confounders.   
 
Methods 
Study protocol, data management and statistical analyses were in collaboration with the 
Robertson Centre for Biostatistics, University of Glasgow according to a pre-specified 
analysis plan (available on request from corresponding author).   
 
Population: Our study used the Generation Scotland resource, specifically the Scottish 
Family Health Study (SFHS) component.  SFHS contains biobanked materials suitable for 
genetic analyses in a well-phenotyped, heterogeneous population of volunteers.  Both 
Generation Scotland and the SFHS have been described in detail elsewhere.(Smith et al 
2012) 
In brief, SFHS is a large, intensively phenotyped, cohort designed to study the genetic basis 
of common, complex diseases. Recruitment began in 2006 and was completed in 2011. 
Individuals were approached through primary care provider.  SFHS contains data on 24 000 
volunteers from across Scotland, aged 18-98. 
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Participants were invited for a detailed clinical assessment, including cognitive tests and 
lifestyle questionnaires.  Blood and urine samples were taken and stored in biobank 
facilities. After participants had given informed consent for data and sample collection and 
analysis, and completed a pre-clinic questionnaire, research nurses/technicians performed 
all measurements. Nurses and technicians were fully trained and validated in sample and 
data collection according to standard operating procedures, each of which was designed for 
the study, according to current best practice. 
 
Polymorphisms of interest: We used a multi-modal approach to select SNPS of interest for 
our study.  Candidate blood markers were chosen based on our previous meta-analysis of 
thrombosis/haemostasis and cognition.  We reviewed the literature for credible genetic 
variables of blood markers using the HuGE Navigator online database resource 
(http://64.29.163.162:8080/HuGENavigator/home.do).  We selected materials where data 
were available from meta-analyses or genetic consortium projects.  We selected SNPs 
based on those with greatest strength of association (the greatest percentage variation in the 
factor) with our blood markers of interest.  We cross referenced plausible SNPs against the 
dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/).  As a final check of face validity we 
consulted with an independent expert in thrombosis/haemostasis (Prof GDO Lowe, 
Glasgow).   We chose to focus our analysis on four exemplar markers of thrombosis / 
haemostasis.  Our final choices of SNP were:  
Fibrinogen:SNP rs1800789 (Chromosome: 4:154561591; gene:FGB. functional 
consequence: upstream variant 2KB).  Chosen based on meta-analysis of GWA study data 
using 91,435 individuals from 28 cohorts of European ancestry with fibrinogen levels and 
genome-wide imputed data.(Dehgan et al 2009) 
D-dimer: SNP rs12029080 (Chromosome: 1:94587797; closest gene: Coagulation factor 3 
(F3)+46.0kb (also known as tissue factor)).  Chosen based on data from Heart and Aging 
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Research in Genomic Epidemiology (CHARGE) Consortium, which includes data from 
several prospective, population-based cohorts of adults in the US and Europe (all European 
ancestry.(Smith et al 2011) 
Von Willebrand factor (vWF): SNP rs1063857 (Chromosome: 12:6044348; Gene:VWF; 
functional consequence: synonymous codon).  Chosen based on data from Atherosclerosis 
Risk in Communities (ARIC) study (European ancestry) (Campos et al 2011, Smith et al 
2010)  and data on expression in cardiovascular disease.(van Schie et al 2011)  
Plasminogen activator inhibitor 1 (PAI-1): SNP rs2227631 (Chromosome: 7:101126257; 
gene:SERPINE1; functional consequence: upstream variant 2KB).  Chosen based on data 
from Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, which 
includes data from several prospective, population-based cohorts of adults in the US and 
Europe (all European ancestry) and Framingham Heart Study data (European ancestry). 
(Huang et al 2012; Kathiresan et al 2005) 
We note that studied SNPs account for only a proportion of variance seen in the markers of 
interest (maximal variance in blood levels explained by SNPs is 2% for fibrinogen variance; 
1.8% for D-dimer; 13% for vWF; 3.7% for PAI-1). 
 
DNA extraction and genotyping: DNA extraction was performed in the Wellcome Trust 
Clinical Research Facility Genetics Core, Edinburgh, UK, using a Nucleon Kit on 9 ml of 
blood sample (Tepnel Life Science). The Picogreen method (Invitrogen) was used to 
quantify DNA concentration in ng/µl, and 500 µl of each DNA master stock was transferred 
to a deep well plate and then normalised to 50 ng/µl to make working stock plates.  The 
plates were then transferred to the British Heart Foundation-Glasgow Cardiovascular 
Research Centre and stored at -4°C for commencement of the genotyping procedure.  Each 
plate held 380 DNA samples in a concentration of 50 ng/µl, with 4 empty wells used as no-
template controls. 
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All genotyping was performed in the British Heart Foundation-Glasgow Clinical Research 
Centre using the TaqMan® OpenArrayTM Genotyping System (Applied Biosciences). 2.5 µl 
of the DNA samples and 2.5 µl of the TaqMan® OpenArray® Master Mix were mixed in the 
TaqMan OpenArray 384-Well sample plate.  The OpenArray Autoloader was used to transfer 
the mixture to TaqMan OpenArray plate.  Thermal cycling was performed using the Dual Flat 
Block GeneAmp® PCR System 9700, applying the appropriate protocol for the TaqMan 
OpenArray plate.  The loaded plates were then scanned using the OpenArray® NT Cycler. 
Genotype calling and results analysis were performed using TaqMan Genotyper Software 
V1.3 (Life Technologies), where results were checked manually to remove samples with 
poor genotype quality.  Genotypes of our 4 SNPs of interest were cross-validated with 
another project that genotyped the same SNPs. 
 
Outcomes of interest: We used data pertaining to a variety of tests that assess differing 
cognitive domains:  
Logical Memory test 1 and 2 (LM1+2) is a test of immediate and delayed auditory memory 
using one story taken from the Wechsler Memory Scale III. In this test a paragraph was read 
to subjects. They were asked to recall the content immediately and after a delay of 30 
minutes.  Scores were total number of memory elements recalled, scores from both tests 
were added together.(Weschler 1998) 
Digit Symbol Test (DST), a measure of processing speed (taken from Wechsler Adult 
Intelligence Scale III).  The participants were instructed to enter symbols according to a 
given number-symbol code. The score recorded was the number of completed symbols 
within 2 min. (Weschler 2013) 
Verbal Fluency test (VF), a measure of phonemic fluency.  Participants were asked to 
name as many words as possible beginning with the letters C,F and L for one minute each.  
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Proper names or repeated words are not credited. The score used was the total number of 
words generated across the three tasks. (Raven 1977)   
We also collected data on the Mill Hill Vocabulary Test (MHVT), a measure of acquired 
verbal knowledge (Junior and Senior synonyms combined) that we used to estimate peak 
prior cognitive ability. (Lezak 1995) 
To assess the importance of other, non-genetic co-variates we included data pertaining to 
demographic factors (age, sex, deprivation [Scottish Index of Multiple Deprivation (National 
Statistics Scotland 2012)]; education [highest level of schooling completed]); lifestyle factors 
(smoking, alcohol, sedentary time [participant estimate]) and clinical factors (blood pressure; 
comorbidity; waist to hip ratio).  Operationalisation of each co-variate has been described 
previously.(Smith et al 2012)  From comorbidity data, we recognised that certain disease 
labels collected in SFHS are potentially associated with  reduced scores on cognitive tests 
and so we grouped these (Alzheimer’s Disease; Parkinson’s Disease and severe 
depression) under a rubric of “cognitive comorbidity”.  For ease of analysis we also created a 
“vascular comorbidity” grouping (hypertension, heart disease [any], stroke, diabetes). 
 
Statistical analysis: Continuous variables were summarised as median (standard 
deviation), median (interquartile range) and range. Categorical variables were summarised 
as number and proportion per category. Distributions of continuous variables were visualised 
using violin plots. All continuous measures showed approximately normal distributions.  To 
obtain maximal statistical power all non-missing data were used resulting in potential 
different sample sizes across variables. 
We assessed the correlation of cognitive variables by Pearson correlation coefficients prior 
to principal component analysis(Table S1).  Then we used principal components analysis to 
derive a general fluid cognitive factor, traditionally called g, (Luciano et al 2011) from the 
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three cognitive tests described above (LM1+2, DST, VF) as the first unrotated component. 
This component explained 49% of the variance from the full cognitive battery. 
To account for family structure, we used mixed models to analyse the relation of the SNP of 
interest to cognitive outcome. To assess whether these relations differ according to age, the 
interaction of the SNP with age group was also entered into the model.  
We analysed the SNPs in four ways, treating them as categorical variables (labelled as 
“factor” in the results tables), as each homozygous category against the two other categories 
(e.g. AA vs. AG or GG and GG vs. AA orAG) and as continuous (labelled as “additive” in the 
results tables). 
We also created multivariable models including socioeconomic and lifestyle factors, 
comorbidities, body measurements and blood pressure variables.  Models were derived 
using a three step process. 
1. Within each domain (socio-economic, blood pressure, body measurements, lifestyle, 
comorbidities), we entered all univariately significant variables into a model predicting 
cognitive factor and used stepwise elimination for all variables with p>0.01.  
2. We entered the remaining variables from all domains together into a model predicting 
cognitive factor and eliminated all variables with p>0.01.  
3. We predicted cognitive factor from all variables identified in step 2 and the SNP. 
We adjusted all mixed models for age, sex and prior peak intelligence (MHVT) and assumed 
a compound symmetry correlation structure within families. 
Recognising that our population was relatively young, and that differences in cognition may 
become apparent with ageing, we conducted a post-hoc sensitivity analysis restricted to 
those aged over 50 years.  In the sensitivity analyses we described scores on cognitive tests 
by allele and mixed models correcting for age, sex and prior peak intelligence. 
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All analyses were performed using R v3.0.1.(R Core Team 2013). The P-values presented 
are not corrected for multiple testing and have to be considered as descriptive.   
 
Results 
Genotyping was performed for 20,753 samples in total, (data on genotype frequencies and 
Hardy Weinberg equilibrium are presented in supplementary materials, Tables S2, S3).  
Of these samples n=465 (2.2%) samples were removed due to poor quality, n=1132 (5.6%) 
were excluded due to implausible SNP data in their family; n=109 (0.5%) were excluded due 
to missing data and n= 121 (0.6%) due to implausible cognitive data.  Genotypes 
discrepancy was less than 1% in over 10,000 genotypes that were cross validated between 
two projects.   
Participants showed a range of cognitive ability on our chosen tests, cognitive scores for 
each test and for combined test (g) are tabulated and presented stratified by age 
(supplementary materials, Table S4).    
The mean age of subjects was 47.3 years (SD:15.0, range:18-99), with11,135 female 
participants (59%).  Level of education was relatively high in the sample with 5,654 (32%) 
having a College/University degree; n=1825 (9.8%) had a marker of cognitive comorbidity.  
Other socio-demographic, clinical, and lifestyle covariates are tabulated (Table 1 and 
supplementary materials, Table S5).   
At traditional significance thresholds, there was no evidence of association between any of 
our four chosen thrombosis/haemostasis related SNPs and any single or combined cognitive 
measures, in uncorrected analyses (Table 1).  Using mixed models accounting for age, sex 
and estimated peak prior intelligence, again there was no evidence of any relevant 
association between SNPs and cognitive ability (Table 2, supplementary materials Tables 
S6).  
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Correcting for co-variates of age, sex and prior peak intelligence, higher scores on (g) were 
significantly associated with lower age, blood pressure, waist-hip ratio, smoking and vascular 
comorbidity and were also associated with higher educational achievement  and 
socioeconomic status (all <0.001), albeit effect sizes were small (Table 3 and supplementary 
materials, Tables S7).  
Our post-hoc sensitivity analyses did not show evidence of association in those aged 50 
years and older.(Table 2 and table 3) 
 
Discussion 
We found no relevant association between genetic polymorphisms associated with 
thrombosis/haemostasis and cognitive abilities in a middle and older age population.  
We postulated that the associations previously described for cognition and circulating 
markers of thrombin generation and endothelial dysfunction were confounded by clinical, 
lifestyle and sociodemographic factors.  We found association between clinical, lifestyle and 
sociodemographic factors and our cognitive domains of interest.  However, we found no 
association between SNPs and cognitive measures, even on uncorrected analysis.  As a 
further check of the robustness of our results, we ran the categorical and additive models 
correcting for plausible demographic, clinical and lifestyle factors that may impact on 
cognition.  Again in these corrected models there was no signal of association.   
Although our data add to our knowledge of determinants of later life cognition, our results are 
not definitive.  We studied a predominantly middle aged and healthy cohort, 
thrombosis/haemostasis genetic associations may still be apparent in older populations with 
greater prevalence of pathological cognitive ageing.  Recognising that our population was 
relatively young, albeit there was a spread of age, we performed post-hoc sensitivity 
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analyses restricted to those aged over 50 years.  Cognitive scores were poorer in the older 
group but again there was no signal of association with our SNPs of interest.   
It is also possible that a modest association may have been missed. The SNPs studied 
account for only a proportion of variance seen in the markers of interest (2% of fibrinogen 
variance; 1.8% for D-dimer; 13% for vWF; 3.7% for PAI-1).  For this reason, many published 
studies using Mendelian Randomisation approaches to describe association with 
thrombosis/haemostasis may have been “under-powered” despite relatively large sample 
sizes.(Welsh 2014; Marioni et al 2011) Thus, given that association between SNPs and 
blood markers is modest and that the association between blood markers and insensitive 
cognitive measures is also modest, even with a large mid-age sample there is potential that 
we lacked statistical “power” to detect a true association.  Confounded association as an 
explanation of previous findings suggesting links between thrombosis and haemostasis are 
also still plausible as our study may have been underpowered to definitively answer this 
question.  Combining our data with other large cohorts that have cognitive and genetic data 
may be necessary to avoid type II statistical error.   
Higher cognitive test scores were seen in those with “healthier” lifestyle, higher education 
and socioeconomic status.  Lower scores were seen in those with vascular risk factors of 
increased blood pressure and waist-hip ratio.  Associations of these factors with cognition 
have been previously described in other cohorts and emphasise the importance of lifestyle 
factors in cognitive ageing.(Barnes et al 2011, Gow et al 2012)  We described prevalent 
psychiatric and neurodegenerative diseases at baseline but numbers were modest.  In a 
population with high prevalence vascular risk factors and disease we had hoped to explore 
possible vascular and non-vascular cognitive decline associations.  Our data do not allow us 
to comment on possible underlying mechanisms for differing cognitive scores. 
Strengths of our approach were access to a large dataset with comprehensive clinical, 
demographic and lifestyle phenotyping including cognitive data and markers of peak prior 
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intelligence.  We used a hypothesis-driven gene-centric analysis informed by systematic 
review of available published data.(Quinn et al 2011) 
A limitation of our work was that we did not have access to participant samples to allow 
quantification of blood levels of D-dimer, fibrinogen, PAI-1 and vWF and this complicates the 
interpretation of our “neutral” result.  We know the strength of association of each SNP with 
the thrombosis/haemostasis markers from pooled genetic data and we know the association 
of each thrombosis/haemostasis marker with cognitive domains of interest from our previous 
meta-analysis.  There is no reason to think the SFHS cohort would be systematically 
different from the cohorts that informed these analyses, but we accept the ideal would have 
been direct blood measures.  
Although our cognitive tests describe various domains these short test data are not 
comparable to the detailed neuropsychological testing that has been used in some previous 
studies looking at associations with later life cognition.(Gow et al 2011)  
We studied only four SNPs that relate to specific circulating factors.  Our chosen SNPs 
represented those with the strongest association with the blood marker of interest.  We 
recognise that other SNPs also contribute to variation in levels of the blood markers (for 
example FV Leiden [rs6025] or prothrombin 3'UTR mutation [rs1799963]) but we were 
limited in the SNPs we could include in our analysis.   Association between 
thrombosis/haemostasis and cognition may still be apparent for those genetic variants that 
make up the remaining variance not accounted for in our chosen SNPs or indeed for other 
genetic markers of thrombosis/haemostasis.  Future studies may wish to explore the 
aggregate effect of combined associated SNPs.   
In conclusion, our Mendelian Randomisation approach did not suggestive a causative 
relationship between circulating markers of thrombosis and haemostasis and cognition.  
Associations were seen with various clinical, demographic and lifestyle factors.  We 
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focussed on a limited number of SNPs and our sample may have been underpowered so a 
causative role for thrombosis/haemostasis is not definitively excluded based on our data.  
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Table 1: Demographic, clinical and lifestyle measures in the Scottish Family Health Study 
cohort 
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Demographic measures                 value 
Age Mean(SD) [Range] 47.3 (15.0) [18.0, 99.0] 
Sex Female - N(%) 11135 (58.8%) 
Education 
College or University degree - N(%) 
Other professional - N(%) 
Higher grade, A level or equivalent - N(%) 
Standard grade or equivalent - N(%) 
No qualifications - N(%) 
5654 (32.2%) 
3600 (20.5%) 
1948 (11.1%) 
2118 (12.1%) 
1424 ( 8.1%) 
SIMD quintile 
1 - N(%) [poorest] 
5 - N(%)[richest] 
2329 (13.3%) 
5525 (31.6%) 
 
Clinical measures 
 
SBP (mmHG) Mean (SD) [Range] 131.5 (17.8) [80.0, 239.0] 
Waist-hip ratio Mean (SD) [Range] 0.9 (0.1) [0.5, 1.7] 
Vasc morbidity Yes - N(%) 3164 (17.1%) 
Cog morbidity Yes - N(%) 1825 ( 9.8%) 
 
Lifestyle measures  
 
Units alcohol in 
last week 
Mean (SD) 
[Range] 
10.1 (13.6) 
[0.0, 326.0] 
Smoking status 
Never - N(%) 
Stopped more than 1 year ago - N(%) 
Current - N(%) 
9700 (52.9%) 
4866 (26.5%) 
3221 (17.6%) 
Sitting hours Mean (SD) [Range] 24.1 (27.9) [0.0, 192.0] 
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Table 1: Demographic, clinical and lifestyle measures in the Scottish Family Health Study 
cohort 
This is an abbreviated table and full details are available in supplementary materials (Table 
S5). 
N obs = Number of observations; N miss= Participants with missing data; SD=Standard 
Deviation; SIMD=Scottish Index of Multiple Deprivation; SBP – Systolic Blood Pressure  
Vasc morbidity = vascular comorbidity; Cog morbidity = Cognitive comorbidity. Vascular and 
cognitive comorbidity are operationalised in the main manuscript.  
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Table 2: Cognitive test scores by single nucleotide polymorphism (SNP) and allele 
SNP Allele 
Allele 
frequency 
Logical 
memory 1+2 
(Total correct) 
[Range: 0-50] 
Digit Symbol 
Testing 
(Total Correct) 
[Range: 0-125] 
Verbal Fluency 
(Total words) 
[Range:0-89] 
Cognitive function 
principal 
component (g) 
  
N (%) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
rs1800789 
AA 
AG 
GG 
623 (3.3%) 
5740 (30.5%) 
12471 (66.2%) 
30.7 (8.6) 
31.0 (7.7) 
31.0 (8.0) 
72.0 (17.1) 
72.3 (16.8) 
72.3 (17.1) 
38.9 (11.5) 
39.7 (11.7) 
39.8 (11.7) 
0.07 (1.25) 
0.00 (1.19) 
0.00 (1.23) 
rs12029080 
GG 
GT 
TT 
1456 (7.7%) 
7694 (40.9%) 
9658 (51.4%) 
31.2 (8.1) 
31.0 (7.9) 
31.0 (8.0) 
72.1 (16.9) 
72.1 (17.0) 
72.3 (17.0) 
39.5 (11.8) 
39.8 (11.7) 
39.7 (11.6) 
0.00 (1.26) 
0.00 (1.20) 
0.00 (1.22) 
rs1063857 
GG 
GA 
AA 
2611 (14.3%) 
8670 (47.5%) 
6956 (38.1%) 
31.0 (7.8) 
31.0 (8.0) 
31.1 (7.9) 
71.7 (17.0) 
72.3 (17.1) 
72.5 (16.9) 
40.1 (11.7) 
39.8 (11.7) 
39.6 (11.6) 
0.01 (1.21) 
-0.01 (1.22) 
-0.01 (1.21) 
rs2227631 
AA 
AG 
GG 
6649 (36.4%) 
8772 (48.1%) 
2831 (15.5%) 
31.2 (8.0) 
31.0 (7.9) 
30.8 (8.0) 
72.3 (17.2) 
72.1 (16.8) 
72.6 (16.8) 
39.7 (11.6) 
39.8 (11.7) 
39.7 (11.5) 
-0.01 (1.23) 
0.00 (1.21) 
0.01 (1.20) 
Sensitivity analysis, cognitive test scores by SNP and allele in participants aged 50 years and older 
rs1800789 
AA 
AG 
GG 
306 ( 3.4%) 
2777 (30.5%) 
6027 (66.2%) 
29.3 (8.5) 
29.8 (7.7) 
29.7 (8.0) 
63.8 (15.1) 
64.8 (15.5) 
64.9 (15.8) 
39.5 (11.7) 
40.5 (12.2) 
40.9 (12.1) 
0.45 (1.22) 
0.34 (1.21) 
0.33 (1.22) 
rs12029080 
GG 
GT 
TT 
698 ( 7.7%) 
3763 (41.3%) 
4645 (51.0%) 
29.4 (8.2) 
29.8 (7.8) 
29.6 (8.0) 
64.4 (15.1) 
64.7 (15.8) 
65.0 (15.8) 
40.1 (12.1) 
40.8 (12.1) 
40.7 (12.1) 
0.40 (1.22) 
0.32 (1.21) 
0.33 (1.22) 
rs1063857 
GG 
GA 
AA 
1281 (14.5%) 
4215 (47.6%) 
3353 (37.9%) 
29.6 (7.9) 
29.7 (7.9) 
29.8 (7.9) 
64.6 (16.2) 
64.8 (15.7) 
65.1 (15.6) 
41.1 (12.3) 
40.8 (12.2) 
40.5 (12.0) 
0.33 (1.25) 
0.33 (1.22) 
0.32 (1.20) 
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SNP Allele 
Allele 
frequency 
Logical 
memory 1+2 
(Total correct) 
[Range: 0-50] 
Digit Symbol 
Testing 
(Total Correct) 
[Range: 0-125] 
Verbal Fluency 
(Total words) 
[Range:0-89] 
Cognitive function 
principal 
component (g) 
  
N (%) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
rs2227631 
AA 
AG 
GG 
3251 (36.7%) 
4262 (48.1%) 
1341 (15.1%) 
29.8 (8.0) 
29.7 (7.8) 
29.5 (8.0) 
64.9 (16.1) 
64.8 (15.5) 
65.1 (15.5) 
40.6 (12.0) 
40.6 (12.2) 
41.0 (11.9) 
0.33 (1.23) 
0.34 (1.21) 
0.33 (1.19) 
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Table 3: Cognitive function and thrombosis/haemostasis genotypes 
 
  
P value  
for variable 
P value (aged 
50 years or 
older) 
P value 
(adjusted 
mixed 
models)  
rs1800789 
AG vs. AA 
GG vs. AA 
p=0.363 p=0.151 p=0.356 
 
Additive p=0.550 p=0.233 p=0.992 
rs12029080 
GT vs. GG 
TT vs. GG 
p=0.731 p=0.254 p=0.552 
 
Additive p=0.546 p=0.683 p=0.423 
rs1063857 
GA vs. GG 
AA vs. GG 
p=0.742 p=0.939 p=0.449 
 
Additive p=0.566 p=0.757 p=0.522 
rs2227631 
AG vs. AA 
GG vs. AA 
p=0.569 p=0.850 p=0.181 
 
Additive p=0.351 p=0.600 p=0.072 
 
P-values from mixed models predicting cognitive principal component “g” from single 
nucleotide polymorphism alleles adjusting for age, interaction of age with single nucleotide 
polymorphism, sex and prior peak intelligence. 
Second results column is sensitivity analyses restricted to those aged over 50 years. 
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Third results column presents models predicting cognitive principal component from SNPs 
and interaction of SNP with age category. Models adjusting for age, sex, mill hill vocabulary 
test, household income, education, blood pressure, heart rate, BMI, waist-hip ratio, alcohol 
consumption, smoking, vascular and cognitive comorbidity history. 
